{"id":690383,"date":"2024-03-05T17:56:02","date_gmt":"2024-03-05T17:56:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=690383"},"modified":"2024-03-05T17:56:02","modified_gmt":"2024-03-05T17:56:02","slug":"alzheimers-disease-pipeline-analysis-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-ab-science-eli-lilly-aribio-novo-nordisk-alector-abbvie","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-pipeline-analysis-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-ab-science-eli-lilly-aribio-novo-nordisk-alector-abbvie_690383.html","title":{"rendered":"Alzheimer&#8217;s Disease Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AB Science, Eli Lilly, AriBio, Novo Nordisk, Alector, AbbVie"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Alzheimer&#039;s Disease Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AB Science, Eli Lilly, AriBio, Novo Nordisk, Alector, AbbVie\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Alzheimer&#039;s Disease Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AB Science, Eli Lilly, AriBio, Novo Nordisk, Alector, AbbVie\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 150+ key pharma and biotech companies are working on 160+ pipeline drugs in the Alzheimer&#8217;s Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Alzheimer&#8217;s Disease Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Alzheimer&#8217;s Disease Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Alzheimer&#8217;s Disease Pipeline report embraces in-depth commercial, regulatory, and Alzheimer&#8217;s Disease clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Alzheimer&#8217;s Disease drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Alzheimer&#8217;s Disease Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the emerging therapies for Alzheimer&#8217;s Disease treatment and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different Alzheimer&#8217;s Disease therapies segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the major Alzheimer&#8217;s Disease companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the Alzheimer&#8217;s Disease drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Alzheimer&#8217;s Disease therapeutic market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/15f6f6fb5d76c1c03be88bd24874c5a9.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Alzheimer&#8217;s Disease Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Approximately <strong>150+ key companies<\/strong> are actively engaged in developing therapies for Alzheimer&rsquo;s Disease, highlighting the significant efforts within the pharmaceutical and biotechnology industries to address this complex neurological condition. Among these companies, those with drug candidates in the most advanced stage, specifically Phase III clinical trials, include <strong>KeifeRx<\/strong>. These companies represent a diverse range of approaches and technologies aimed at tackling Alzheimer&rsquo;s Disease, offering hope for patients, caregivers, and healthcare professionals. As research progresses and clinical trials advance, the potential for innovative therapies to positively impact the lives of those affected by Alzheimer&rsquo;s Disease continues to grow.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Alzheimer&#8217;s Disease Companies Actively Working in the Therapeutic Market Include:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Some of the key companies in the Alzheimer&#8217;s Disease Therapeutics Market include <strong>Cassava Sciences, KeifeRx, AB Science, Eli Lilly and Company, BioVie Inc., AriBio Co., Ltd., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, True Binding, Inc., AbbVie, and Shanghai Hengrui Pharmaceutical Co., Ltd.<\/strong> and others.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emerging and Marketed Alzheimer&#8217;s Disease Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Nilotinib: KeifeRx<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AR1001: AriBio Co., Ltd.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">LY3372689: Eli Lilly &amp; Co.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many Others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Alzheimer&#8217;s Disease Companies Working in the Market:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Alzheimer&#8217;s Disease Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report covers the emerging products under different phases of clinical development like &#8211;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued and inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Alzheimer&rsquo;s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal Antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polymer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene therapy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Alzheimer&#8217;s Disease Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Alzheimer&#8217;s Disease Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Alzheimer&#8217;s Disease &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Alzheimer&#8217;s Disease Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Alzheimer&#8217;s Disease Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Alzheimer&#8217;s Disease Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Alzheimer&#8217;s Disease Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Alzheimer&#8217;s Disease Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Major Alzheimer&#8217;s Disease Companies in the Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Alzheimer&#8217;s Disease Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Alzheimer&#8217;s Disease Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Alzheimer&#8217;s Disease Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Alzheimer&#8217;s Disease Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-on-chronic-liver-failure-aclf-market\">Acute On Chronic Liver Failure (ACLF) Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Acute On Chronic Liver Failure (ACLF) Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute On Chronic Liver Failure market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Acute On Chronic Liver Failure market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=alzheimers-disease-pipeline-analysis-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-ab-science-eli-lilly-aribio-novo-nordisk-alector-abbvie\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/medical-devices\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/medical-devices<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/medical-devices\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=alzheimers-disease-pipeline-analysis-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-ab-science-eli-lilly-aribio-novo-nordisk-alector-abbvie\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 150+ key pharma and biotech companies are working on 160+ pipeline drugs in the Alzheimer&#8217;s Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-pipeline-analysis-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-ab-science-eli-lilly-aribio-novo-nordisk-alector-abbvie_690383.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,417,406,404],"tags":[],"class_list":["post-690383","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/690383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=690383"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/690383\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=690383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=690383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=690383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}